[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"androgenic-alopecia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:androgenic-alopecia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,43,71,97,125,153,180,214,239,262,286,314,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643276","study-to-evaluate-xtress-gummy-supplement-in-men-with-androgenic-alopecia-100643276",false,"NCT07637071","Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia","A Multi-center, Randomized, Double-Blind, Placebo- Controlled Pilot Study to Evaluate the Efficacy and Safety of Xtressé™ Gummy-Based Nutraceutical Supplement in Men With Androgenic Alopecia","Inclusion Criteria:\n\n* Males aged 18-65\n* Norwood III to IV, vertex focused\n* Fitzpatrick skin type I to VI\n* Ability and willingness to comply with study protocol\n\nExclusion Criteria:\n\n* Change in other hair treatments in 3 months prior to study enrollment.\n* Known uncontrolled health conditions.\n* History of hair or scalp disorders that could interfere with study results.\n* History of metabolic syndrome.","MALE","18 Years","65 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss). Forty-eight participants will be randomly assigned to receive either Xtresse' active gummy or placebo. Neither staff not participant will know which treatment is given.\n\nThe main aims of this trial are:\n\n1. To confirm using photographic analysis, changes in the quality, volume, and thickness of hair.\n2. To gauge patient satisfaction with hair changes and application process.\n3. Monitor and report any adverse events associated with the daily intake of Xtressé\n\nParticipants who qualify will complete 3 in-person visits. Participants will be given a 90-day supply of the gummies at visits 1 (after voluntary consent is given) and 2 to cover the 6-month study period. Photographs and scalp analysis will be performed at each visit to measure changes in hair volume, thickness, and growth.",[27,28,29],"Androgenic Alopecia","Hair Loss\u002FBaldness","Hair Thinning","NOT_YET_RECRUITING","2026-08-13",{"date":33,"type":34},"2026-08-17","ACTUAL",{"date":36,"type":21},"2026-09-29",{"date":38,"type":21},"2027-06",{"name":40,"class":41},"Restore Biologics Holdings, Inc. dba Xtressé","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100322193","early-phase-1-evaluating-the-efficacy-of-platelet-rich-plasma-therapy-in-the-treatment-of-androgenic-alopecia-100322193","NCT03474718","Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia","Inclusion Criteria:\n\n* Female ≥18 years of age at baseline visit.\n* Documentation of androgenic alopecia diagnosis as evidenced by one or more clinical features\n* Not currently on any treatment for alopecia, or has undergone 2-week washout period if recently on medication(s) for alopecia\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Have an infection, metastatic disease or certain skin conditions (ie. Psoriasis) which could worsen or spread with injections\n* Diagnosed with a blood or bleeding disorder\n* Diagnosed with anemia\n* Currently on anticoagulant therapy","FEMALE",{"count":51,"type":21},16,[53],"EARLY_PHASE1","The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.",[27],[57,58,59],"scalp","hair loss","platelet-rich plasma therapy","2026-08-03",{"date":62,"type":34},"2026-08-04",{"date":64,"type":21},"2026-10",{"date":66,"type":21},"2027-07",{"name":68,"class":69},"Wake Forest University Health Sciences","OTHER",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100638850","a-clinical-study-to-evaluate-the-efficacy-and-safety-of-ultra-in-promoting-hair-regrowth-100638850","NCT07588243","A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth","A Pivotal Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth","Inclusion Criteria:\n\n* 22 - 70 years old\n* Is willing to undergo study device use.\n* Fitzpatrick skin type I-VI\n* Clinical diagnosis of androgenetic alopecia (Norwood-Hamilton II-V or Ludwig I-II)\n* Willing to avoid significant changes to hair (such as drastic haircuts and dying hair) during their involvement in the study.\n* Willing to maintain current diet and exercise routine throughout study duration.\n* Understands and accepts the study condition to not receive any other procedures to the treatment area or to undergo any procedures, take any medications, supplements, or partake in any other treatments indicated for hair growth throughout the length of the study.\n* Understands and accepts the study condition of and agrees that he or she is able to be present for all study visits.\n* Willing to comply with all requirements of the study and is able to provide written informed consent.\n\nExclusion Criteria:\n\n* Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding, or planning a pregnancy during the study period.\n* Has a diagnosis of other forms of alopecia (e.g., scarring alopecia, alopecia areata)\n* Has recent use (within 6 months) of a systemic hair growth medications (e.g., oral finasteride).\n* Inconsistent use of vitamins that can affect hair growth - must have stabilized use for at least 6 months prior to first treatment.\n* Had previous treatment (such as laser or topical) to scalp within 6 months.\n* Has a malignant disease, cancer, or uncontrolled medical condition.\n* Has an impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications","ALL","22 Years","70 Years",{"count":82,"type":21},44,[24],"The goal of this clinical study is to evaluate the efficacy and safety of the Ultra device for the treatment of hair regrowth by assessing the improvement of hair density and hair shaft diameter.",[27],[27],"RECRUITING","2026-05-22",{"date":90,"type":34},"2026-05-27",{"date":92,"type":34},"2026-02-19",{"date":94,"type":21},"2026-12",{"name":96,"class":41},"CynosureLutronic",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":70},"100636234","jak2-expression-in-androgenetic-alopecia-before-and-after-topical-minoxidil-100636234","NCT07563036","JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil","Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.","Inclusion Criteria:\n\n* Male adults aged 18 to 50 years with androgenetic alopecia.\n* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.\n* Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Other types of hair loss, including inflammatory or scarring alopecia.\n* Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.\n* Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.\n* History of severe systemic disease, including renal, cardiovascular, or hepatic disease.\n* Chemotherapy during the last 5 years.\n* Bleeding disorders.",true,"50 Years",{"count":107,"type":21},25,[24],"Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.",[111,27],"Androgenetic Alopecia",[27,113,114,115],"Janus Kinase 2","JAK2","minoxidil","2026-04-25",{"date":118,"type":34},"2026-05-01",{"date":120,"type":34},"2026-02-01",{"date":122,"type":21},"2027-01-01",{"name":124,"class":69},"Kasr El Aini Hospital",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":78,"minAge":17,"maxAge":105,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":70},"100631614","topical-2-deoxy-d-ribose-hydrogel-versus-minoxidil-5-solution-for-androgenetic-alopecia-100631614","NCT07502976","Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia","Efficacy & Safety of Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution in Treatment of Androgenetic Alopecia: A Clinical & Biochemical Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 50 years.\n* Male and female patients with androgenetic alopecia.\n* Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V in males and Ludwig scale I to II in females.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Other types of hair loss, including inflammatory or scarring alopecia.\n* Psoriasis.\n* Inflammatory scalp dermatoses.\n* History of severe systemic disease, including renal, cardiovascular, or hepatic disease.\n* Chemotherapy during the last 5 years.\n* Pregnancy.\n* Lactation.\n* Bleeding disorders.",{"count":133,"type":21},60,[24],"Androgenetic alopecia is a common form of hair loss that can affect quality of life. This randomized controlled trial aims to evaluate the efficacy and safety of topical 2-Deoxy-D-ribose (2dDR) hydrogel compared with topical minoxidil 5% solution in the treatment of mild to moderate androgenetic alopecia in adults aged 18 to 50 years. Sixty participants will be randomized into 2 treatment groups. The 2dDR group will apply 1 gram of topical 2dDR hydrogel once daily to the affected scalp areas for 6 months. The minoxidil group will apply topical minoxidil 5% solution to the affected scalp areas for 6 months according to sex-specific dosing in the protocol.\n\nParticipants will undergo clinical assessment, trichoscopic evaluation, and standardized scalp photography at baseline, Week 12, and Week 24. The study will also assess tissue vascular endothelial growth factor (VEGF) levels using scalp biopsy specimens obtained at baseline and after 3 months of treatment in both groups. Safety will be evaluated through adverse event monitoring and clinical scalp examination during follow-up visits.",[27],[138,139,140,141,142,143,144],"Male Pattern Hair Loss","Female Pattern Hair Loss","2-Deoxy-D-ribose","2dDR Hydrogel","Hair Loss","Trichoscopy","VEGF","2026-03-31",{"date":147,"type":34},"2026-04-06",{"date":149,"type":34},"2026-01-01",{"date":151,"type":21},"2027-01",{"name":124,"class":69},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":70},"100626390","phase-3-androgenic-alopecia-th07-clinical-trial-100626390","NCT07435012","Androgenic Alopecia TH07 Clinical Trial","Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.","MATT","Inclusion Criteria:\n\n* Males, 18 to 49 years of age on the date of enrollment.\n* Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.\n* Body Mass Index (BMI) in the range of 19 to 35 kg\u002Fm2.\n* Not administered any systemic or topical treatment for AGA during the last 90 days.\n* Willing to comply with the following restrictions for the duration of trial participation:\n\n  1. Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.\n  2. Hair dyes, hair texturizers, relaxers etc.\n  3. Any new vitamins or nutritional supplements that are currently not being administered.\n  4. Tattooing in the trial target area.\n  5. Blood donations.\n  6. OTC hair restorers.\n  7. Do not expose your pregnant partner to your hands\u002Fskin where the drug might be present.\n  8. Participation in any other drug or device trials during the course of this trial.\n\n     Note: However, the following shall be permissible:\n  9. Non-medicated \\& anti-dandruff shampoos, scalp\u002Fhair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.\n  10. Current regimen (if any) of vitamins and nutritional supplements.\n* Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.\n* Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.\n\nExclusion Criteria:\n\n* History of scalp treatment including though not limited to any of the following:\n\n  1. Hair transplant or extension surgery.\n  2. Hair weaving.\n  3. Laser or light therapy on the scalp in the last 6 months.\n  4. Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.\n\n  5-Any other surgical treatment for hair loss\n* Any of the following hair styles:\n\n  1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.\n* Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.\n* Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.\n* History or likelihood of use of any of the specified medicines.\n* History or clinical diagnosis of any of the specified medical conditions.\n* Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.\n* Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.","49 Years",{"count":163,"type":21},420,[165],"PHASE3","The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.",[27],[142,169,27,170],"Hair growth","Balding","2026-03-12",{"date":173,"type":34},"2026-03-16",{"date":175,"type":21},"2026-04",{"date":177,"type":21},"2028-04",{"name":179,"class":41},"Triple Hair Inc",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":104,"sex":78,"minAge":17,"maxAge":18,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":193,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":70},"100601234","autologous-hair-follicle-secretome-for-androgenic-alopecia-single-site-100601234","NCT07107841","Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)","Blinded, Randomized, Controlled, Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for the Treatment of Androgenic Alopecia (Single Site)","Inclusion Criteria\n\n* SUBJECTS MUST BE ON A STABLE COURSE OF MINOXIDIL (ORAL OR TOPICAL) AND\u002FOR 5-ALPHA REDUCTASE INHIBITORS. THEY MUST HAVE BEEN ON THE SAME 5-ALPHA REDUCTASE INHIBITOR FOR ≥12 MONTHS PRIOR TO BASELINE.\n* FEMALE SUBJECTS MUST NOT BE ON HAIR GROWTH MEDICATIONS OR TOPICALS FOR ≥6 MONTHS PRIOR TO BASELINE.\n* TESTOSTERONE REPLACEMENT THERAPY (TRT) IN ANY FORM (E.G. DEPO-, INJECTABLE, TOPICAL, PATCHES, NASAL GEL, ORAL, PELLET ETC.) IS ALLOWED AS LONG AS SUBJECT HAS BEEN ON A STABLE COURSE (IN THE OPINION OF THE INVESTIGATOR) OF TRT FOR ≥12 MONTHS.\n* Biological sex: Male and Female (up to n=20 males and up to n=10 females will be in each arm for a total of up to n=40 males and up to n=20 females)\n* Age: ≥18 - 65 years\n* Subjects with Androgenic alopecia\n* No intention to start new hair growth medications and no intention to change the dosage or usage of minoxidil or 5-alpha reductase inhibitors until the end of their participation in the trial.\n* Competent and willing to provide written, informed consent to participate in all study activities.\n* Willing and able to tolerate multiple injections of the study product.\n* Must be able to attend all study related clinical visits.\n* Willing to maintain the same hair style as at the Screening Visit for the duration of the study.\n* Must be willing to have small (diameter similar to a pencil lead) UV (invisible) or red colored tattoo dots applied to scalp (up to 5) and touch up tattoos if necessary. UV tattoo dots only show under black light. Subjects will chose UV or red.\n\nExclusion Criteria\n\n* Subjects with clinical diagnosis of alopecia areata or other non-androgenic forms of alopecia.\n* Active skin disease (Psoriasis or severe seborrheic dermatitis) of the scalp\n* Scalp infection\n* Severe active systemic infection\n* Cuts or abrasions on the scalp\n* History of surgical hair restoration in the last 12 months.\n* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers)\n* History of systemic chemotherapy or radiation\n* History of thyroid dysfunction\n* History of autoimmune disorder (specifically Graves disease, Hashimoto thyroiditis, or systemic lupus erythematosus)\n* Continuous\u002Fdaily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.\n* Use of any medications that potentially cause drug-induced hair loss (e.g., depo-testosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.\n* Known allergy or sensitivity to tattoo ink.\n* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban; warfarin\u002Fcoumarins)\n* Significant tendency to develop keloids or hypertrophic scarring\n* Subjects unable to communicate with the investigator and staff\n* Any health condition that in the investigator's opinion should preclude participation in this study",{"count":133,"type":21},[24],"(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365.\n\nHair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.",[27,191,192],"Alopecia","Baldness",[194,195,196,197,198,199,200,57,58,201,202,203,204],"secretome","alopecia","Hair","stem cells","androgenic","androgenetic","Hormone","baldness","bald","hair follicle","Acorn","2026-02-10",{"date":207,"type":34},"2026-02-12",{"date":209,"type":34},"2025-10-16",{"date":211,"type":21},"2027-09-15",{"name":213,"class":41},"Acorn Biolabs Inc.",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":70},"100621625","umbilical-cord-mesenchymal-stem-cell-derived-exosomes-in-the-treatment-of-androgenic-alopecia-100621625","NCT07373054","Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia","Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia: A Prospective, Randomized, Controlled Clinical Trial","Inclusion Criteria:\n\n* Male, aged 18 to 60 years (inclusive), in good general health.\n* Clinical diagnosis of androgenetic alopecia (AGA) according to the 2023 Chinese Clinical Practice Guideline: Diagnosis and Treatment of Androgenetic Alopecia, with a disease duration of less than 5 years and a Hamilton-Norwood scale classification of stage II to IV at the screening visit.\n* Able to fully understand the study's content, procedures, potential benefits, and risks, and willing to provide written informed consent prior to any study-specific procedures.\n* Agrees to comply with the study protocol and refrain from using any other treatments for alopecia for the duration of the study.\n\nExclusion Criteria:\n\n* Unwilling or unable to provide written informed consent.\n* History of any malignancy within the past 5 years (except for adequately treated non-scalp basal cell carcinoma or squamous cell carcinoma in situ).\n* Hypotension (blood pressure \\\u003C 90\u002F60 mmHg) documented within 1 month prior to screening, or uncontrolled hypertension within 3 months prior to screening (defined as failure to achieve a target of \\\u003C 140\u002F90 mmHg while on a stable regimen of at least two antihypertensive medications).\n* Known history of any systemic disease that may affect hair growth or confound study assessments (e.g., HIV infection, connective tissue disease, inflammatory bowel disease, hypothyroidism, iron deficiency anemia, malnutrition, syphilis).\n* Known history of other forms of non-androgenetic alopecia (e.g., diffuse alopecia, alopecia areata, cicatricial alopecia).\n* History of major organ dysfunction, significant autoimmune disease, or immunodeficiency.\n* Known coagulation disorders, current use of anticoagulant or antiplatelet therapy (except low-dose aspirin), thrombophilia, or inherited bleeding disorders.\n* Treatment with chemotherapy, cytotoxic drugs, scalp radiation, or laser\u002Fsurgical hair restoration within 12 months prior to screening.\n* History of hair transplantation, or need for long-term use of wigs, hairpieces, or hair bonding agents during the trial.\n* History of severe or multiple drug allergies, atopy, known allergy to local anesthetics, or planned desensitization therapy during the study period.\n* Presence of any active dermatological condition in the target scalp area that could interfere with evaluation (e.g., infection, seborrheic dermatitis, psoriasis, eczema, folliculitis, open wounds, scars, or atrophy).\n* Participation in another interventional clinical trial within 4 weeks prior to screening (except for non-interventional studies or participants who only signed the informed consent form without receiving any investigational product).\n* Any other medical or psychiatric condition that, in the judgment of the investigator, would compromise the subject's safety, compliance, or suitability for study participation.","60 Years",{"count":223,"type":21},18,[24],"Androgenic Alopecia(AGA) is a highly prevalent condition for which existing pharmacological and surgical interventions present limitations and side effects, creating a clinical need for safer and more effective therapies. In response, human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy. Characterized by their rich bioactive components, absence of tumorigenic risk, and high safety profile, hUCMSC-Exos represent a promising approach for hair regeneration. This study aims to evaluate the safety and efficacy of hUCMSC-Exos combined with automated microneedle delivery for treating AGA. By utilizing innovative lyophilization technology to maintain exosomal bioactivity and employing precision microneedle systems for enhanced delivery, this research seeks to provide a new generation solution for androgenic alopecia treatment.",[27],[27,228,229],"stem cell","exosome","2026-01-28",{"date":232,"type":34},"2026-01-30",{"date":234,"type":34},"2025-11-06",{"date":236,"type":21},"2027-05-01",{"name":238,"class":69},"Fujian Medical University Union Hospital",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":78,"minAge":17,"maxAge":105,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100613992","phase-3-comparison-of-outcomes-between-topical-minoxidil-versus-oral-minoxidil-for-the-treatment-of-androgenetic-alopecia-100613992","NCT07273799","Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia","mina","Inclusion Criteria:\n\n* Patients with androgenic alopecia Norwood-Hamilton class 2-6 in males and Sinclair class 2-5 in females\n* History of androgentic alopecia for at least 1 year\n* 18 to 50 years of age\n* Willing to provide informed consent\n* Willing to not use any other hair loss treatment during the treatment period\n\nExclusion Criteria:\n\n* History of cardiovascular disease\n* Use of some other hair restoration therapy in the past 6 months such as minoxidil, finasteride or PRP\n* Presence of other causes of alopecia (e.g., alopecia areata, scarring alopecia).\n* Pregnant and lactating females\n* Previous Hair Transplantation\n* Patients with a known hypersensitivity to the study drug or class of study drug\n* Patients with co-morbid conditions like chronic liver disease, chronic kidney disease, neurological or psychiatric disorders\n* Presence of any other autoimmune disease (especially thyroid disease)",{"count":247,"type":21},200,[165],"To compare the outcome of topical minoxidil 5% spray versus oral minoxidil 2.5 mg tablet for the treatment of androgenetic alopecia in males and females. Outcomes include efficacy of the treatment, measured by reduction in hair shedding, improvement in hair density and new hair growth as assessed by physican and patient assessment as well as safety, defined as incidence and severity of adverse events over a treatment period of 6 months",[27],[27,252],"Minoxidil","2025-12-05",{"date":255,"type":34},"2025-12-10",{"date":257,"type":21},"2025-12-20",{"date":259,"type":21},"2026-06-01",{"name":261,"class":69},"Sheikh Zayed Federal Postgraduate Medical Institute",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":269,"maxAge":105,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":4},"100615052","comparison-between-platelet-rich-plasma-and-nanofat-as-an-adjuvant-therapy-in-hairtransplantation-100615052","NCT07287579","Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in HairTransplantation","Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in Hair Transplantation in Male Androgenic Alopecia","Inclusion Criteria:\n\n* 1\\. Male patients with stable androgenic alopecia more than 2 years. 2. Age 20-50 years 3. No recent medical hair loss treatments.\n\nExclusion Criteria:\n\n* 1\\. Active scalp infections or scarring alopecia. 2. Systemic diseases affecting wound healing. 3. Platelet disorders or anticoagulant use. 4. Smoking or heavy alcohol intake","20 Years",{"count":271,"type":21},30,[24],"* To compare the efficacy of platlet rich plasma and Nanofat injection as adjuvant therapies with FUE hair transplantation in improving graft survival rate,\n* To measure hair density and thickness postoperatively using dermoscopy or trichoscopy.\n* To evaluate patient satisfaction and photographic assessment by blinded evaluators.\n* To assess any adverse effects or complications related to each modality",[27],[276],"hair transplantation","2025-12-03",{"date":279,"type":34},"2025-12-17",{"date":281,"type":21},"2026-01",{"date":283,"type":21},"2027-12",{"name":285,"class":69},"Sohag University",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":297,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":70},"100608595","phase-1-a-study-on-the-treatment-of-androgenetic-alopecia-in-young-men-with-umbilical-cord-mesenchymal-stem-cell-exosomes-100608595","NCT07203599","A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","A Randomized Controlled Clinical Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","MSCs treatment","Inclusion Criteria:\n\n* 1\\. Male patients aged 18-35 2. Clinically diagnosed with androgenic alopecia, Hamilton Norwood Scale III-V 3. Patients who voluntarily participate in clinical trials and sign informed consent forms\n\nExclusion Criteria:\n\n* 1\\. Known alcohol allergy 2. Patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney, endocrine, or hematopoietic system 3. Patients with other scalp diseases or hair loss diseases 4. Patients with severe mental illness and cognitive impairment 5. Patients with poor nutritional status and low immune function 6. Within 1 year, those who have used systemic corticosteroids, immunosuppressants, cytotoxic drugs, and peripheral vasodilators 7. Within 6 months, those who have used systemic or local drugs to treat hair loss, such as finasteride, minoxidil, etc 8. Within 3 months, those who have received other clinical trial drugs 9. Family genetic history or other criteria considered unsuitable by researchers","35 Years",{"count":296,"type":21},59,[298,299],"PHASE1","PHASE2","This clinical trial aims to determine the efficacy of human umbilical cord mesenchymal stem cell exosomes (hUCMSC-sEV) in treating androgenic alopecia in young men. It will also investigate the safety of hUCMSC-sEV. The primary inquiry it seeks to address is:\n\n* Do hUCMSC-sEV demonstrate efficacy in the treatment of androgenic alopecia in young men?\n* Do hUCMSC-sEV safely used to treat androgenic alopecia in young men?\n\nThe clinical trial has two parts. The Phase I study is a dose-escalation trial. Researchers will determine the appropriate dosage of hUCMSC-sEV. The Phase II study is a randomized controlled trial. Researchers will evaluate hUCMSC-sEV against a placebo (minoxidil tincture) to determine the efficacy of hUCMSC-sEV in treating androgenic alopecia in young men.\n\nIn the phase I study, participants will be categorized into three dosage groups: A, B, and C. In Group A, one injection site will be allocated for each 1 cm² of hair loss area, delivering a dosage of 1.0×10\\^8 particles per site. In Group B, the dosage will be 1.0×10\\^9 particles per site. In Group C, the dosage will be 1.0×10\\^10 particles per site. Participants will attend the clinic at weeks 0, 2, 4, and 6 for treatment and assessments. Participants will also attend the clinic for follow-up examinations at weeks 8, 12, and 24.\n\nIn the phase II study, participants will be randomly allocated in a 1:1 ratio to two groups: the hUCMSC-sEV treatment group and the minoxidil treatment group. hUCMSC-sEV treatment group: the appropriate dose of hUCMSC-sEV for the phase II study was determined based on assessments of safety, tolerability, and preliminary efficacy from the phase I study. Participants will receive one injection site for each 1 cm² of hair loss area. Participants will attend the clinic for therapy and assessments at weeks 0, 2, 4, and 6. Minoxidil treatment group: participants will get 1 mL of minoxidil administered daily to the area of hair loss for 12 consecutive weeks. All patients will attend the clinic for follow-up examinations at weeks 8, 12, and 24.",[27],[303,304],"androgenic alopecia","human umbilical cord mesenchymal stem cell exosomes","2025-11-24",{"date":307,"type":34},"2025-12-02",{"date":309,"type":34},"2025-09-20",{"date":311,"type":21},"2026-11-01",{"name":313,"class":69},"Shenzhen People's Hospital",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":269,"maxAge":80,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":42},"100511371","computer-assisted-hair-restoration-study-using-artas-system-100511371","NCT05938569","Computer-Assisted Hair Restoration Study Using ARTAS System","Inclusion Criteria:\n\n* Subject is male with clinical diagnosis of androgenetic alopecia with Norwood-Hamilton grade of III-VI\n* Subject is 20 to 70 years old\n* Subject agrees to cut hair short (\\\u003C 1 mm) on the scalp in the designated study areas for harvesting and implantation\n* Subject is able to understand and provide written consent\n* Subject consents to post-operative follow-up per protocol\n\nExclusion Criteria:\n\n* Subject has prior history of scalp reduction surgery(s) in the past six months\n* Subject has bleeding diathesis\n* Subject has active use of anti-coagulation medication\n* Subject has any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study",{"count":321,"type":21},150,[24],"Prospective, multi-center, up to 4 investigational centers evaluating the performance of the ARTAS System in Hair Restoration Procedures.",[27],"2024-08-22",{"date":327,"type":34},"2024-08-26",{"date":329,"type":4},"2016-11-03",{"date":331,"type":21},"2026-12-15",{"name":333,"class":41},"Venus Concept",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":4},"100541169","autologous-stromal-vascular-fraction-in-treatment-of-male-androgenic-alopecia-100541169","NCT06326359","Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia","Evaluation of Safety and Efficacy of Autologous Stromal Vascular Fraction Derived From Denovo Versus Platelet Rich Plasma Enhanced Donner Site in Treatment of Male Androgenic Alopecia","Inclusion Criteria:\n\n* Male patients with androgenic alopecia\n\nExclusion Criteria:\n\n* Patients with other hair loss disorders as telogen effluvium, anagen effluvium, alopecia areata, cicatricial alopecia and trichotillomania.\n\nAny other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area.\n\nAny systemic disease as autoimmune disorders , cardiac hepatic and renal patients.\n\npatients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study","55 Years",{"count":343,"type":21},40,[24],"Evaluation of Safety and efficacy of autologous stromal vascular fraction derived from denovo versus platelet rich plasma enhanced donner site in treatment of male androgenic alopecia",[27],[348,349,350],"autologous stromal vascular fraction","platelet rich plasma","male androgenic alopecia","2024-03-16",{"date":353,"type":34},"2024-03-22",{"date":355,"type":21},"2024-03",{"date":64,"type":21},{"name":285,"class":69}]